文献速递泌尿生殖与妇科肿瘤放疗

单次大剂量HDR近距离放疗作为局限性前列腺癌单一疗法的英国国家队列早期结果

Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study.
PubMed 文献 · Radiother Oncol · 2020-02-07

英国七中心国家方案纳入441例局限性前列腺癌患者,给予单次19 Gy HDR近距离放疗,中位随访26个月。3年生化无复发生存率总体88%,低危100%、中危86%、高危及75%;仅Gleason评分是独立预测因素,急性毒性低,但随访尚短。

要点

  • 单次19 Gy HDR近距离放疗在低危前列腺癌3年bRFS达100%。
  • 中危和高危3年bRFS分别为86%和75%,复发主要位于前列腺。
  • 急性毒性无3-4级事件,晚期尿道狭窄和3级直肠事件各2例。

核心结论

  • 单次19 Gy HDR近距离放疗在低危局限性前列腺癌中3年bRFS为100%,但中危和高危结果较差,分别为86%和75%,复发主要位于前列腺。
  • 受随访时间短限制,该单次HDR方法的长期结局仍不确定,需密切监测队列随数据成熟。

研究设计与样本

  • 英国七中心协作的国家方案,评估单次19 Gy HDR近距离放疗作为局限性前列腺癌单一疗法。
  • 共纳入441例患者,中位随访26个月(范围2-56),中位年龄73岁(范围54-84)。
  • 入组允许所有风险组,但要求PSA≤40 µg/L且分期检查无转移;PTV为前列腺包膜加3 mm外扩,并设定尿道和直肠规划约束。

主要发现

  • 风险分组:低危10%、中危65%、高危及25%;37.6%总体接受ADT,高危及90%接受ADT,中位疗程6个月。
  • 3年bRFS总体88%:低危100%、中危86%、高危及75%;仅Gleason评分是bRFS的独立预测因素。
  • 25例复发经影像学评估,其中15例发生在前列腺,11例仅为局部前列腺复发。
  • 急性毒性低,无3级或4级事件;晚期出现2例尿道狭窄和2例3级直肠事件。

关键数值与推荐

  • 主要终点为生化无复发生存率(bRFS),采用Phoenix定义。
  • 毒性采用CTCAE v4.0评估。
  • 处方剂量为单次19 Gy,PTV定义为前列腺包膜加3 mm外扩。

临床怎么用

  • 单次19 Gy HDR近距离放疗可作为低危局限性前列腺癌的选择之一,但中危和高危需谨慎评估。
  • 治疗后应密切监测生化指标,尤其在中危和高危患者中关注前列腺局部复发。

局限性

  • 随访时间较短(中位26个月),长期结局不确定。
  • 单臂队列研究,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HDR brachytherapy alone is effective for the treatment of localised prostate cancer when given in 2-4 or more fractions. Single dose treatment has been explored in small cohort studies to date. This paper reports a large patient population with localised prostate cancer treated with single dose HDR brachytherapy delivering 19 Gy providing early outcome data from this approach. PATIENTS AND METHODS: Seven centres across the UK collaborated in this national protocol to deliver 19 Gy to the PTV defined by the prostate capsule and a 3 mm expansion with clearly defined planning constraints for the urethra and rectum. Entry criteria allowed all risk groups provided PSA ≤40 µg/L and staging investigations were negative for metastases. The primary end point was biochemical relapse free survival (bRFS) defined using the Phoenix definition. Toxicity was measured using CTCAE v4.0. RESULTS: A total of 441 patients were entered with median follow up 26 months (range 2-56). Median age was 73 (range 54-84) and 10% were low risk, 65% intermediate risk and 25% high risk. ADT was received by 37.6% overall and 90% of high risk patients for a median period of 6 months. Three year bRFS was overall 88%: this was 100% in low risk, 86% in intermediate risk and 75% in high risk. Only Gleason score was an independent predictor of bRFS. Relapse in 25 patients was assessed radiologically and occurred in the prostate in 15 of these, 11 of whom had localised prostate relapse only. Acute toxicity was low with no grade 3 or 4 events; there were two cases of late urinary stricture and two grade 3 late rectal events. CONCLUSION: This is the largest cohort of single dose HDR brachytherapy patients treated with a single dose published to date. It shows that with 19 Gy there is 100% bRFS at 3 years in low risk patients but results in intermediate and high risk groups are less encouraging falling to 86% and 75% at 3 years with relapse predominantly in the prostate. Limited by the short follow up period of this study, the long-term outcomes of this single dose HDR approach remains uncertain. It is important to have close ongoing surveillance of this cohort as the data matures.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tharmalingam H, Tsang Y, Ostler P, et al. Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. Radiother Oncol. 2020. PMID: 32044166. doi:10.1016/j.radonc.2019.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。